Sun Pharma launches CEQUA®, a novel therapy for Dry Eye Disease in India
First dry eye treatment available in India that is delivered with nanomicellar (NCELL ® ) * Technology Unique NCELL ®* Technology and formulation provides superior delivery over cyclosporine emulsion 0.05% i Backed by several years of clinical experience in the U.S. and other geographies. Mumbai, India, April 25, 2023 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomb: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has launched a novel ophthalmology treatment, CEQUA ® , in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition. CEQUA ® is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL ® ) * technology. Kirti Ganorkar, CEO – India Business, Sun Pharma, said, “Current treatment optio...